| 10th week of 2009 patent applcation highlights part 49 |
| Patent application number | Title | Published |
|---|
| 20090060790 | SENSOR FOR DETECTING SUBSTANCE IN LIQUID - A sensor for detecting a substance in liquid includes a sensing circuit including a sensing surface acoustic wave (SAW) element in which a reaction film to react with a substance in liquid, a reference circuit including a reference SAW element including an IDT and not including a reaction film, a first signal source driving the sensing circuit, a second signal source driving the reference circuit and being independent of the first signal source, and a differential circuit arranged to output a differential output between an output of the sensing circuit and an output of the reference circuit. The frequency of a first frequency signal output from the first signal source is different from the frequency of a second frequency signal output from the second signal source, thereby making a driving frequency for the sensing SAW element and a driving frequency for the reference SAW element substantially the same as or different from one another. | 2009-03-05 |
| 20090060791 | MICROCHANNEL CHIP AND METHOD FOR MANUFACTURING SUCH CHIP - The present invention provides a microchannel chip having microchannels fabricated without using an original such as a mold. The microchannel chip of the present invention comprises at least an upper substrate and a lower substrate, the upper substrate and the lower substrate being bonded together, characterized in that at least one non-bonding thin-film layer is formed on the bonding side of at least one substrate and that opposite ends of the non-bonding thin-film layer are each connected to a port open to the atmosphere. When a positive pressure is applied through one port, the area that corresponds to the non-bonding thin-film layer inflates to create a gap that can function as a microchannel, with the result that a liquid and/or a gas can be transferred from one port to the other. | 2009-03-05 |
| 20090060792 | AUTOMATIC ANALYZER - An automatic analyzer includes a B/F separator including a reaction vessel holding unit provided with magnets disposed around a reaction vessel held on the reaction vessel holding unit, a rotating device for rotating the reaction vessel holding unit holding the reaction vessel about an axis of rotation aligned with the center axis of the reaction vessel or an axis of rotation parallel to and separated by a distance from the center axis of the reaction vessel. Both magnetic force and centrifugal force are exerted simultaneously on a specimen contained in a reaction vessel to capture magnetic particles contained in the liquid contained in the reaction vessel at a high capturing efficiency. | 2009-03-05 |
| 20090060793 | MICRODISPENSER AND ASSOCIATED OPERATING METHOD - The invention relates to a microdispenser ( | 2009-03-05 |
| 20090060794 | Eccentric rotating device - A motor driven rotating device is disclosed that includes a fixed base, an eccentric rotating mechanism above the base, first magnets in the base, and second magnets in the rotating mechanism. A polarity of each first magnet is opposite to that of each second magnet so as to maintain a gap between the base and the rotating mechanism. Also, the rotating mechanism is adapted to eccentrically rotate. | 2009-03-05 |
| 20090060795 | MICROFLUIDIC DEVICES WITH INTEGRATED RESISTIVE HEATER ELECTRODES INCLUDING SYSTEMS AND METHODS FOR CONTROLLING AND MEASURING THE TEMPERATURES OF SUCH HEATER ELECTRODES - The invention relates to methods and devices for control of an integrated thin-film device with a plurality of microfluidic channels. In one aspect, the present invention provides a method for controlling the temperature of a heater electrode associated with a microfluidic channel of a microfluidic device, wherein power applied to the heater electrode is regulated by varying the duty cycle of a pulse width modulation (PWM). In another aspect, the present invention a controller configured to compute the temperature of the heater electrode during the power-on portion of the duty cycle and the during the power-off portion of the duty cycle and to adjust the duty cycle as necessary to achieve a desired temperature in the heater electrode. | 2009-03-05 |
| 20090060796 | Acoustic Liquid Dispensing Apparatus - A liquid dispensing apparatus for dispensing droplets of a liquid, and methods for measuring various fluid parameters of the liquid are described. The liquid dispensing apparatus comprises a container having a chamber for holding a liquid. An orifice is positioned at an end of the chamber for dispensing droplets of the liquid, the orifice being configured to retain the liquid in the container if the container is positioned with the orifice facing in a downward direction. An acoustic transducer means is at least partially positioned in the chamber for periodically propagating a focused acoustic beam toward the orifice and through at least some of the liquid while the liquid is contained in the chamber, with the focused acoustic beam being capable of causing a droplet of the liquid to be ejected from the orifice when a free surface of the liquid is within the depth of field of the acoustic transducer means. Fluid parameters that can be measured include the sound velocity in the liquid, liquid level and liquid concentration, liquid acoustic impedance, liquid density ultrasonic attenuation and ultrasonic viscosity. | 2009-03-05 |
| 20090060797 | FLUID CONTROL STRUCTURES IN MICROFLUIDIC DEVICES - Methods and apparatus for implementing microfluidic analysis devices are provided. A monolithic elastomer membrane associated with an integrated pneumatic manifold allows the placement and actuation of a variety of fluid control structures, such as structures for pumping, isolating, mixing, routing, merging, splitting, preparing, and storing volumes of fluid. The fluid control structures can be used to implement a variety of sample introduction, preparation, processing, and storage techniques. | 2009-03-05 |
| 20090060798 | Automated Endoscope Reprocessor Germicide Concentration Monitoring System and Method - A method measures a property of a germicidal solution in an endoscope processor spectroscopically by placing a quantity of the solution into a cuvette and passing a light therethrough. A reservoir receives a quantity of the solution and bubbles are filtered out via a cross-flow filter prior to putting a sample therefrom into the cuvette for measuring. | 2009-03-05 |
| 20090060799 | Adjustable tabletop air freshener - We describe an adjustable table-top air freshener composed of a case that comprises an internally hollow body, provided with four pairs of slots arranged in couples around the perimeter of its lateral wall, and a cover which presents through-holes in its surface. The case body is designed to hold four absorbent pieces of aromatizing product, executed in twos with a three-point star and circular configuration with alternately sunken and protruding portions on its perimeter edge, of a diameter slightly smaller than the inside diameter of the case body and stacked alternately in the interior of the case body, with a star-shaped piece occupying the bottom position. The cover presents the formation of ribs of a predetermined height protruding from its inner face, interposed respectively between successive openings, which assure the separation between said cover and the absorbent piece located in the upper position. | 2009-03-05 |
| 20090060800 | Substrate Mounting System - A support system for a fragile substrate of an exhaust gas treatment device includes a microporous, inorganic insulating layer, which directly or indirectly engages at least a portion of the fragile substrate: and a flexible fibrous mounting mat which directly or indirectly engages at least a portion of said fragile substrate. The support system may support the fragile substrate of a catalytic converter, a diesel particulate trap filter, a selective catalyst reduction unit, or a NO | 2009-03-05 |
| 20090060801 | METHOD FOR PRODUCING NITROGEN TO USE IN UNDER BALANCED DRILLING, SECONDARY RECOVERY PRODUCTION OPERATIONS AND PIPELINE MAINTENANCE - The invention uses a feed of atmospheric air and mixes the air with hydrogen. The hydrogen and air mixture is fed into a catalytic reactor where a deoxygenation reaction occurs. The deoxygenation reaction uses a platinum catalyst to produce water from oxygen and hydrogen. The nitrogen passes through the catalytic reactor without reacting with the hydrogen, the oxygen, or the water. The water is separated from the nitrogen in a dryer. The nitrogen may then be used in drilling and production operations. The water is fed into an electrolyzer where an electrolysis reaction occurs. The electrolyzer passes an electrical current through the water to produce gaseous oxygen and hydrogen. The hydrogen is recycled back to the catalytic reactor and the oxygen may be vented or sold. | 2009-03-05 |
| 20090060802 | EXHAUST GAS TREATMENT DEVICE - A mounting mat for an exhaust gas treatment device including inorganic fibers, organic binder, antioxidant, optionally clay and optionally intumescent material. The exhaust gas treatment device includes a housing, a fragile catalyst support structure resiliently mounted within the housing, and the mounting mat disposed in a gap between the housing and the fragile catalyst support structure. Additionally disclosed are methods of making a mounting mat for an exhaust gas treatment device and for making an exhaust gas treatment device incorporating the mounting mat. | 2009-03-05 |
| 20090060803 | Hybrid Refinery for Co-Processing Biomass With Conventional Refinery Streams - The present invention is generally directed to methods and systems for processing biomass into usable products, wherein such methods and systems involve an integration into conventional refineries and/or conventional refinery processes. Such methods and systems provide for an enhanced ability to utilize biofuels efficiently, and they can, at least in some embodiments, be used in hybrid refineries alongside conventional refinery processes. | 2009-03-05 |
| 20090060804 | SEMICONDUCTOR PHOTOELECTRODE, METHOD FOR MANUFACTURING THE SAME, AND LIGHT ENERGY CONVERTING DEVICE - The semiconductor photoelectrode of the present invention includes a metallic substrate having irregularities in a surface and a semiconductor layer which is formed on the surface of the metallic substrate and composed of a photocatalytic material. This can increase the light absorption efficiency and, furthermore, prevent recombination of charges. | 2009-03-05 |
| 20090060805 | Process and apparatus for hydrogen and carbon production via carbon aerosol-catalyzed dissociation of hydrocarbons - The present invention relates to a novel process for sustainable, continuous production of hydrogen and carbon by catalytic dissociation or decomposition of hydrocarbons at elevated temperatures using in-situ generated carbon particles. Carbon particles are produced by decomposition of carbonaceous materials in response to an energy input. The energy input can be provided by at least one of a non-oxidative and oxidative means. The non-oxidative means of the energy input includes a high temperature source, or different types of plasma, such as, thermal, non-thermal, microwave, corona discharge, glow discharge, dielectric barrier discharge, or radiation sources, such as, electron beam, gamma, ultraviolet (UV). The oxidative means of the energy input includes oxygen, air, ozone, nitrous oxide (NO | 2009-03-05 |
| 20090060806 | SNCR DISTRIBUTION GRID - An SNCR distribution grid for introducing a NOx reducing reactant into a flue gas flow. The grid is made of one or more elements which are formed by fluid-cooled tubes to which membrane pieces are attached, preferably by welding, to form conduits in between the tubes. The fluid-cooled tubes may be cooled by water and/or steam and the distribution grid is disposed in the flue gas flow. To admit the reactant into the flue gas, nozzles are provided in the membrane and the reactant is conveyed from a location external of the furnace or combustor enclosure, into the conduits so formed, and thence out into the Flue gas flow via the nozzles. | 2009-03-05 |
| 20090060807 | PROCESS FOR REMOVING SULFUR FROM A FUEL GAS STREAM - Disclosed is a process for removing sulfur from a fuel gas stream that comprises an organic sulfur compound and a light olefin. The process includes introducing a fuel gas stream into an elongated hydrotreating reactor vessel in which it is contacted with a hydrodesulfurization catalyst under hydrodesulfurization process conditions. A quench gas stream is also introduced into the elongated hydrotreating reactor vessel at a location below the point of introduction of the fuel gas stream. A reactor effluent is yielded that contains hydrogen sulfide and a significantly reduced organic sulfur concentration that is below the organic sulfur concentration of the fuel gas stream. | 2009-03-05 |
| 20090060808 | Scrubber For Reactive Gases - Scrubber media for reactive gases, that can include but are not necessarily limited to hydrogen chloride (HCl), hydrogen sulfide (H | 2009-03-05 |
| 20090060809 | Ammonia Decomposition Catalyst and Process for Decomposition of Ammonia Using the Catalyst - Disclosed is a catalyst useful for catalytic decomposition of high concentration ammonia, and also disclosed is a process for decomposing ammonia using the catalyst. As the ammonia decomposion catalyst, a catalyst which supports a metallic element selected from Fe, Co, Ni and Cu by ion exchange method on porous silica alumina having an Si/Al atomic ratio of 1 to 90 and a specific surface area of 200 to 900 m | 2009-03-05 |
| 20090060810 | Preparation Method of Vanadium/Titania-Based Catalyst Showing Excellent Nitrogen Oxide-Removal Performance at Wide Temperature Winow Through Introduction of Ball Milling, and Use Thereof - Disclosed are a method for preparing a catalyst, which has excellent nitrogen oxide-removal performance and resistance over a wide temperature range, and the use of the catalyst. According to the disclosed method, the oxidation number and surface defects of the catalyst are changed by applying artificial high energy through mechanical ball milling during the preparation process of the catalyst, instead of applying the addition of a precious metal, the deformation of a support and the use of a co-catalyst in order to increase NOx removal activity, such that activation energy for inducing redox reactions can be decreased. | 2009-03-05 |
| 20090060811 | Wide Mesoporous Alumina Composites Having Trimodal Pore Structure - Wide mesoporous alumina composites are produced by an “in situ reaction” route comprising agglomeration of an alumina powder that is capable of rehydration together with a second reactive powder such as carbonate. In one method of production, the powders are fed to a rotating forming device that is continuously sprayed with liquid under conditions to form particulates. The discharging beads are then subjected to curing and thermal activation to produce the final catalyst or adsorbent. The alumina participates in a pore altering process involving the carbonate component upon formation of hydroxycarbonate intermediates such as Dawsonite. Large fraction of the pore volume of the final product consists of wide mesopores in the 15-50 nanometers range. The alumina composites exhibit a characteristic trimodal pore structure that includes also small micro-meso pores and macropores larger than 200 nanometers. | 2009-03-05 |
| 20090060812 | MEDICAL RADIOISOTOPES AND METHODS FOR PRODUCING THE SAME - This disclosure concerns a new method for preparing radioisotopes, such as molybdenum-99, by alpha particle irradiation, such as by alpha particle irradiation of zirconium-96. Molybdenum-99 is a precursor to the medically-significant radioisotope technetium-99m. Also disclosed are novel compositions containing one or more of technetium-99m, molybdenum-99 and zirconium species. Systems for producing molybdenum-99 and technetium-99m, including alpha particle generators and irradiation targets, also are described. | 2009-03-05 |
| 20090060813 | MOLECULAR SIEVE SSZ-82 COMPOSITION OF MATTER AND SYNTHESIS THEREOF - The present invention is directed to a new crystalline molecular sieve designated SSZ-82, a method for preparing SSZ-82 using a 1,6-bis(N-cyclohexylpyrrolidinium)hexane dication as a structure directing agent, and uses for SSZ-82. | 2009-03-05 |
| 20090060814 | METHOD OF PRODUCING FLUOROAPATITE, FLUOROAPATITE, AND ADSORPTION APPARATUS - A method of producing fluoroapatite by using a calcium-based compound containing calcium, hydrogen fluoride and phosphoric acid is provided. The method can be produced fluoroapatite having improved acid resistance by reducing an amount of an impurity derived from a raw material to a low or very low level, and ability capable of separating a large amount of a protein due to a large specific surface area thereof. Further, fluoroapatite having high acid resistance and a large specific surface area is also provided. Furthermore, an adsorption apparatus using such fluoroapatite is also provided. | 2009-03-05 |
| 20090060815 | Silylated carbon nanotubes and methods of making same - The invention provides adducts comprising a carbon nanotube with covalently attached silane moieties, and methods of making such adducts. Examples of silane moieties include trimethoxysilane; hexaphenyldisilane; silylphosphine; 1,1,1,3,5,5,5-heptamethyltrisiloxane; polydimethylsiloxane, poly(N-bromobenzene-1,3-disulfonamide); N,N,N′,N′-tetrabromobenzene-1,3-disulfonamide; hexamethyldisilazane (HMDS); chlorotrimethylsilane (TMCS); trichloromethylsilane (TCMS); an alkyl(alkylamino)silane; a tri(alkoxy)silane; tert-butyldimethylsilane; monochloroaminosilane; dichloroaminosilane; trichloroaminosilane; and dimethylaminosilane. | 2009-03-05 |
| 20090060816 | MESOPOROUS SILICA PARTICLES AND PRODUCTION PROCESS THEREOF - A process for wet pulverizing mesoporous silica particles while a surfactant exists in mesopores, and mesoporous silica particles having an average particle diameter of 1 μm or less, wherein the volume of mesopores having a diameter of 2 to 50 nm is 0.7 mL/g or more and the geometric standard deviation of a mesopore distribution is 2.0 or less. Mesoporous silica particles having a particle diameter in a submicron order can be obtained at a high yield without causing the marked collapse of mesopores and can be produced efficiently by using an ordinary pulverizer and safely by using an aqueous medium. The mesoporous silica particles having an average particle diameter of 1 μm or less are useful as an ink absorbent for ink jet recording paper, low-dielectric film, catalyst support, separating agent, adsorbent and medical carrier for medicines. | 2009-03-05 |
| 20090060817 | METHOD FOR PRODUCING TRICHLOROSILANE - A by-product mixture produced in a process for producing polycrystalline silicon is made to react with chlorine to form tetrachlorosilane (STC) distillate in a chlorination reaction vessel, and the tetrachlorosilane (STC) distillate is made to react with hydrogen in a hydrogenation reaction vessel to be converted into trichlorosilane (TCS). In the chlorination step, methyl chlorosilanes having boiling points close to TCS are hyper-chlorinated to be converted into hyper-chlorinated methyl chlorosilanes having higher boiling points, which facilitates the hyper-chlorinated methyl chlorosilanes to be separated into high concentration, and inhibits carbon from contaminating the polycrystalline silicon. A donor/acceptor eliminator is provided in the circulation cycle for producing TCS, and accordingly there is no need to take out a by-product produced in the process for producing TCS to the outside of the system, which can highly purify the TCS. | 2009-03-05 |
| 20090060818 | SILICON AND CATALYST MATERIAL PREPARATION IN A PROCESS FOR PRODUCING TRICHLOROSILANE - A process for preparing trichlorosilane by reacting silicon with hydrogen chloride, or silicon tetrachloride with hydrogen in the presence of silicon, and catalysts where the silicon and catalysts are laminated together and reduced in particle size prior to reaction. | 2009-03-05 |
| 20090060819 | PROCESS FOR PRODUCING TRICHLOROSILANE - A process for preparing high purity trichlorosilane (TCS) utilizing contaminated by-products of primary reaction products hydrogen chloride, metallurgical or chemical grade silicon stock, and/or by-products of the improved Siemens process, including “dirty” TCS containing low boiling impurities such as dichlorosilane (DCS) and “dirty” STC containing high boiling impurities. The “dirty” STC is first purified and a portion is reacted with “dirty” TCS containing DCS to produce additional TCS feedstock for the TCS purification process. Another portion of the purified STC is hydrogenated and converted back to TCS providing another feedstock to the TCS purification process. Overall net yield of high purity TCS produced is increased over established practice. | 2009-03-05 |
| 20090060820 | METHOD FOR PRODUCING TRICHLOROSILANE AND METHOD FOR PRODUCING POLYCRYSTALLINE SILICON - The present invention includes a step of separating an effluent produced in a hydrogenation step of making tetrachlorosilane (STC) react with hydrogen into trichlorosilane (TCS), into a chlorosilane fraction containing a hydrocarbon and a TCS fraction, and a chlorination step of making the chlorosilane fraction containing the hydrocarbon react with chlorine to form STC and a substance containing a chlorinated hydrocarbon, wherein the effluent containing STC produced in the chlorination step is circulated to the hydrogenation step. In the chlorination step, the chlorosilane fraction containing a hydrocarbon (capable of containing hyper-hydrogenated chlorosilanes) having a boiling point close to TCS is hyper-chlorinated to be converted and acquire a higher boiling point, which facilitates the hyper-chlorinated chlorosilanes and the hyper-chlorinated hydrocarbons to be separated into high concentration, and increases the purity of TCS to be finally obtained. | 2009-03-05 |
| 20090060821 | METHOD FOR MANUFACTURING SILICONE WAFERS - The method of manufacturing silicon wafers from one or more silicon blocks or bricks includes etching at least one lateral surface of a silicon block or brick using a mixture of highly oxidative acids and then forming a plurality of wafers by sawing the silicon block or brick. During the etching of the lateral surface a mean amount of material removed is 3 to 160 μm thick and the material is isotropically removed with a constant mean material removal speed of from 1 to 20 μm/min across the entire lateral surface. Prior to the etching treatment the silicon block or brick is advantageously subjected to an abrasive grinding or polishing. The mixture of acids is preferably a mixture of 50 to 70% nitric and 40 to 60% hydrofluoric acids in a ratio range of 8:1 to 4:1. | 2009-03-05 |
| 20090060822 | METHOD FOR PRODUCING POLYCRYSTALLINE SILICON - A by-product mixture produced when polycrystalline silicon is deposited on a base material in a CVD reactor is made to react with chlorine to form a tetrachlorosilane (STC) effluent in a chlorination reaction vessel, and the tetrachlorosilane (STC) distillate is made to react with hydrogen in a hydrogenation reaction vessel to be converted into trichlorosilane (TCS). In the chlorination step, poly-silane contained in the above described by-product mixture can be efficiently recycled as a raw material for producing the polycrystalline silicon, which can enhance a yield of the production process. In addition, in the chlorination step, methyl chlorosilanes having boiling points close to TCS are hyper-chlorinated to be converted into hyper-chlorinated methyl chlorosilanes having higher boiling points, which facilitates the hyper-chlorinated methyl chlorosilanes to be separated into high concentration, and reduces carbon contamination of the polycrystalline silicon. | 2009-03-05 |
| 20090060823 | Reduced Wetting String for Ribbon Crystal - A string for use in a string ribbon crystal has a base portion with a refractory material, and an externally exposed layer radially outward of the refractory material. The base portion has a coefficient of thermal expansion that is generally matched with the coefficient of thermal expansion for silicon. The externally exposed layer has a contact angle with silicon of between about 15 and 120 degrees. | 2009-03-05 |
| 20090060824 | Washing method, washing apparatus for polycrystalline silicon and method of producing polycrystalline silicon - A washing method comprising: cleaning polycrystalline silicon with an acid solution; soaking of the polycrystalline silicon in a soaking bath in which pure water is stored; and measuring an electrical conductivity of the pure water in the soaking bath, wherein, in the soaking, the polycrystalline silicon is immersed in the pure water stored in the soaking bath, and the pure water in the soaking bath is replaced at least once to remove the acid solution remaining on a surface of the polycrystalline silicon; and in the measuring, completion of the soaking is determined based on measured values of the electrical conductivity | 2009-03-05 |
| 20090060825 | PRODUCTION METHOD OF NANOPARTICLE - A production method of nano-sized silicon crystal particles comprising the step of allowing monosilane to be oxidized in a liquid phase. | 2009-03-05 |
| 20090060826 | Apparatus and Method for Continuous High Temperature Gas Treatment of Particulate Matter - An object of the present invention is to provide an apparatus for continuous high temperature gas treatment of particulate matter, which can perform uniform high temperature gas treatment of particulate matter; and a method for treating particulate matter using the continuous high temperature gas treatment of particulate matter. | 2009-03-05 |
| 20090060827 | METHOD FOR GROWING CARBON NANATUBES HAVING A PREDETERMINED CHIRALITY - A method for growing carbon nanotubes having a determined chirality includes fragmenting at least one initial carbon nanotube having a determined chirality to obtain at least two portions of carbon nanotube. Each portion has a free growth end. Atoms of carbon are supplied with an autocatalyst addition of the atoms of carbon at the free growth end of each portion of nanotube to determine an elongation or growth of the nanotube. | 2009-03-05 |
| 20090060828 | Fluorine Extraction Process For Fluoro-Refractory Coatings And Articles Manufactured According To Said Process - A process for extracting fluorine from a fluoro-refractory coating includes the steps of providing an article having a fluoro-refractory coating; treating hydrothermally the fluoro-refractory coating at a temperature and for a period time sufficient to liberate a quantity of fluoride from the fluoro-refractory coating; and drying a hydrothermally treated article. | 2009-03-05 |
| 20090060829 | Cold-walled vessel process for compounding, homogenizing and consolidating semiconductor compounds - A method is provided for compounding, homogenizing and consolidating compounds. In one embodiment, the charge components are mixed in a controlled addition process, then the newly-formed compound is heated to become totally molten, followed by a rapid quench at room temperature. In an alternate embodiment, the components are supplied with an excess of one component acting as a solvent, heated to dissolve additional components, and then the solvent is separated from the compound to produce homogeneous consolidated compounds. The methods herein are advantageously applied to provide an economical and fast process for producing CdTe, CdZnTe and ZnTe compounds. | 2009-03-05 |
| 20090060830 | METHOD FOR MANUFACTURING A NANOPOROUS FRAMEWORK AND A NANOPOROUS FRAMEWORK THUS PRODUCED - The invention concerns a method for manufacturing nanoporous metal oxide or metal active sites frameworks in which the metal oxide precursor is distributed into the framework in the form of a metal soap surfactant. | 2009-03-05 |
| 20090060831 | Fine-particulate lead zirconium titantes zirconium titanate hydrates and zirconium titanates and method for production thereof - The invention relates to fine-particulate zirconium titanates or lead zirconium titanates and a method for production thereof by reaction of titanium dioxide particles with a zirconium compound or a lead and zirconium compound. The titanium dioxide particles have a BET surface of more than 50 m | 2009-03-05 |
| 20090060832 | HYDROGEN STORAGE USING POROUS CARBON NANOSPHERES - Hydrogen is stored by adsorbing the hydrogen to a carbon nanomaterial that includes carbon nanospheres. The carbon nanospheres are multi-walled, hollow carbon nanostructures with a maximum diameter in a range from about 10 nm to about 200 nm. The nanospheres have an irregular outer surface and an aspect ratio of less than 3:1. The carbon nanospheres can store hydrogen in quantities of at least 1.0% by weight. | 2009-03-05 |
| 20090060833 | Fuel Compositions for Fuel Cells and Gas Generators Utilizing Same - In a reaction of water or other reactable liquids with solid borohydride fuels, the liquid reactant and/or additives are converted to a gel form ( | 2009-03-05 |
| 20090060834 | METHOD FOR PREPARING NES-TYPE ZEOLITES USING NOVEL STRUCTURE DIRECTING AGENTS - The present invention is directed to a process for preparing NES-type zeolites using novel nitrogen-based structure directing agents. | 2009-03-05 |
| 20090060835 | METHOD FOR PREPARING SSZ-26/33 ZEOLITES USING NOVEL STRUCTURE DIRECTING AGENTS - The present invention is directed to a process for preparing zeolites belonging to the SSZ-26/33 family of zeolites using novel nitrogen-based structure directing agents | 2009-03-05 |
| 20090060836 | DERIVATIVES OF 2-NITRO-1,3-IMIDAZOLE COUPLED TO AMINO ACIDS AND DEOXYRIBOSE USEFUL FOR THE DETECTION OF HYPOXIC BIOLOGICAL TISSUE - The present invention relates to a 2-nitroimidazole derivative, a diagnostic pharmaceutical composition which contains such 2-nitroimidazole derivative, the use of the 2-nitroimidazole derivative for the detection of hypoxic biological tissue as well a method for the detection of hypoxic biological tissue by the use of the 2-nitroimidazole derivative. | 2009-03-05 |
| 20090060837 | COBALAMIN CONJUGATES USEFUL AS ANTITUMOR AGENTS - The invention provides cobalamin compounds linked to a neutron capture therapy target (e.g. Boron-10 or Gadolinium-157), and optionally linked to a detectable moiety, as well as pharmaceutical compositions comprising the compounds, and methods for using the compounds in medical diagnosis and therapy. | 2009-03-05 |
| 20090060838 | SUBSTITUTED N-ARYL BENZAMIDES AND RELATED COMPOUNDS FOR TREATMENT OF AMYLOID DISEASES AND SYNUCLEINOPATHIES - Substituted n-aryl benzamides, related compounds and their pharmaceutically acceptable salts, their synthesis and labeling, pharmaceutical compositions containing them, and their use in the treatment of amyloid diseases, including Aβ amyloidosis, such as observed in Alzheimer's disease, IAPP amyloidosis, such as observed in type 2 diabetes, and synucleinopathies, such as observed in Parkinson's disease, and the manufacture of medicaments for such treatment are provided. Also provided is the use of the disclosed compounds as imaging agents and methods for in vivo imaging and diagnosis of amyloid and synuclein diseases. | 2009-03-05 |
| 20090060839 | Gold Nanoparticle Conjugates and Uses Thereof - The disclosure generally relates to formation of polymers grafted to or polymerized from the surface of gold nanoparticles. The polymers are functionalized to include therapeutic agents and/or targeting agents at their surface, thereby allowing both therapeutic and targeting compounds to be directed to specific cells in a patient. | 2009-03-05 |
| 20090060840 | Lanthanide Nanoparticle Conjugates and Uses Thereof - The present disclosure is directed generally to lanthanide nanoparticle conjugates, such as gadolinium nanoparticle conjugates, nanoparticle conjugates including polymers, conjugation to targeting agents and therapeutic agents, and their use in targeting, treating, and/or imaging disease states in a patient. | 2009-03-05 |
| 20090060841 | APPARATUS AND METHOD FOR COMBINED USE OF VARIABLE FLIP ANGLES AND CENTRIC PHASE ENCODING IN HYPERPOLARIZED 13C IMAGING - A system and method for MR imaging includes a magnetic resonance imaging (MRI) system having a plurality of gradient coils positioned about a bore of a magnet, and an RF transceiver system and an RF switch controlled by a pulse module to transmit RF signals to an RF coil assembly to acquire MR images. The apparatus further includes a controller programmed to determine a variable flip angle (VFA) sequence to excite a hyperpolarized material in a subject and to determine a delay period during which application of the VFA sequence is delayed after injection of a hyperpolarized contrast agent. The delay period is based on dynamic data of the hyperpolarized material acquired from the subject. The controller is also programmed to cause application of the VFA sequence to excite the hyperpolarized material in the subject and to acquire MR data from the hyperpolarized material using an isotropic centric phase encoding (iCPE) technique. | 2009-03-05 |
| 20090060842 | METHOD FOR DIAGNOSIS AND TREATMENT OF PROSTATITIS - In a method for diagnosis and treatment of a patient with regard to prostatitis, a differential diagnosis of prostatitis versus prostate cancer and/or BPH is conducted on a patient using a cost-effective diagnosis method. Given diagnosed prostatitis, a cost-effective decision test is implemented on the patient to determine whether the patient exhibits complaints locally in the region of the prostate or in the rest of the body. A molecular inflammation marker is administered to the patient, wherein a cost-effective imaging method is implemented in the region of the prostate of the patient given local complaints or a cost-intensive imaging method is implemented on the entire patient given complaints in the rest of the body. An inflammation-inhibiting treatment is implemented in the body region of the patient that is detected as inflamed via the respective imaging method. | 2009-03-05 |
| 20090060843 | Non-Invasive In Vivo Imaging and Methods for Treating Type I Diabetes - The present invention provides novel drug discovery platforms and methods for treating type I diabetes. | 2009-03-05 |
| 20090060844 | METHOD AND CONTRAST AGENT FOR IMAGING A PROSTATE TUMOR - In a method for imaging a prostate tumor in which a contrast agent that can be distributed via the circulatory system is administered to the patient, the contrast agent contains at least one type of biomarkers which are bound to a ferromagnetic particle and specifically bind to a target molecule typical of the tumor and formed within the tumor or in a tissue adjacent to the tumor. The imaging ensues with the use of magnetic resonance tomography. | 2009-03-05 |
| 20090060845 | DIAGNOSIS SUBSTANCE FOR APPLICATION IN A METHOD TO DIAGNOSIS PATHOLOGICAL TISSUE AND A METHOD FOR PRODUCTION OF SUCH A DIAGNOSIS SUBSTANCE - A diagnosis substance for application in a method for diagnosis of pathological tissue, contains at least one virus population with virus particles specifically binding to target molecules typical of a specific pathological tissue, with a label that is detectable with the use of a detection device being bound to the virus particles. In a method for production of such a diagnosis substance, the principle of directed biological evolution is applied. | 2009-03-05 |
| 20090060846 | NANOPARTICLES HAVING REACTIVE ESTER GROUPS COVALENTLY COUPLED THERETO AND RELATED METHODS - A particle having a core and a surface to which are covalently coupled a plurality of reactive ester groups. Methods for using the particle to prepare a particle having one or more of a plurality of a targeting agent, a diagnostic agent, or a therapeutic agent covalently coupled thereto. | 2009-03-05 |
| 20090060847 | CONTRAST AGENT FOR ULTRASOUND EXAMINATION OF THE PROSTATE AND METHOD TO DIAGNOSE PROSTATE CANCER - A contrast agent for ultrasound examination of the prostate has contrast-intensifying particles on an exterior of which at least one binding molecule is present that specifically binds to CEACAM-1. In a method for ultrasound examination of the prostate, such a contrast agent is administered to the patient and a sonography of the prostate is subsequently implemented. | 2009-03-05 |
| 20090060849 | Personal care compositions comprising certain dye-polymer complexes - The present invention relates to personal care compositions comprising certain dye-polymer complexes. Additionally, methods for coloration of personal care compositions using said dye-polymer complexes are disclosed. | 2009-03-05 |
| 20090060850 | ERICACEA EXTRACTS FOR COMBATING SKIN AGING - Extracts of plants of the Ericacea family are administered to individuals to combat the signs of aging of the skin, e.g., wrinkles and fine lines, for example by inhibiting the expression of metalloproteases, by inhibiting collagen degradation, or by inhibiting UV-induced skin degradation. | 2009-03-05 |
| 20090060851 | USE OF IDEBENONE FOR THE PREPARATION OF A TOPICALLY-APPLIED DEPIGMENTATION COMPOSITION AND CORRESPONDING COMPOSITION - The invention relates to the use of idebenone for the preparation of a topically-applied composition which is intended to inhibit melanogenesis, to reduce cutaneous coloration or to brighten same and/or produce cutaneous depigmentation. More specifically, the invention relates to a topically-applied composition comprising a cosmetic, pharmaceutical and/or dermatologically-effective amount of idebenone, derivatives thereof or mixtures of same, in which there is an effective amount of idebenone or the derivative thereof such as to produce cutaneous depigmentation. | 2009-03-05 |
| 20090060852 | Compounds, Formulations and Methods for Reducing Skin Wrinkles, Creasing and Sagging - Methods, compounds, and topical formulations for reduction of skin sagging, creasing and/or wrinkling are disclosed. The methods comprise topically applying a composition comprising an α2 adrenergic receptor agonist. Amelioration of skin sagging, creasing and/or wrinkling begins within minutes after topical application of a disclosed composition. A single application can significantly reduce skin sagging, creasing and/or wrinkling for at least about 8 hours. | 2009-03-05 |
| 20090060853 | Aminophenylbenzothiazole compounds - The Use, as a UV filter, of a compound of formula | 2009-03-05 |
| 20090060854 | Dermatological Compound - A topically-applied composition for the treatment of the dermal and subcutaneous skin layers combines selected sulfonated glycosaminoglycans and two anti-oxidizing compounds in a pharmaceutically acceptable carrier. A constituent to treat damage due to ultraviolet A and/or B light can be added to the composition. Differing formulations are provided for daytime and evening application. | 2009-03-05 |
| 20090060855 | Bleaching composition comprising a non-volatile liquid branched ester of carboxylic acid with solidification point below 4°C - The present disclosure relates to compositions for the bleaching of keratinous fibers comprising at least one peroxygenated salt and at least one non-volatile liquid branched ester of a carboxylic acid, the solidification point of which is below 4° C., chosen from the compounds with the following structure: R | 2009-03-05 |
| 20090060856 | Colorant Composition For Skin Cosmetics, Foundation Containing The Same, And Method Of Makeup Application - The object of the invention is to provide a colorant composition for skin cosmetics, that can provide a natural texture while retaining hiding power, a foundation containing the same, and a method of makeup application. A colorant composition for skin cosmetics of the present invention is characterized in that the colorant composition, which contains nonwhite coloring materials, does not contain a high refractive index white pigment, and when the spectral reflectance of the colorant composition is measured under the below-described measurement conditions, the minimum spectral reflectance on the white ground in the wavelength range of 630-700 nm is 75% or higher, and the Y value on the white ground is in the range of 25-65 (Measurement conditions) A colorant composition is dispersed in nitrocellulose lacquer, the concentration of the colorant composition is adjusted so that the spectral reflectance on the white ground of a black and white hiding test paper at the wavelength of 400 nm is 10±2%, a black and white hiding test paper is coated with an applicator having a 0.101 mm clearance, and the spectral reflectance is measured with a spectrocolorimeter. | 2009-03-05 |
| 20090060857 | LIP GLOSS - Embodiments of inventive subject matter described herein include a lip gloss comprising: a sugar gel matrix that includes stearoyl inulin and an ester or ether of formula R(1) COOR(2) in which R(1) is a residue of a fatty acid including from 6 to 29 carbon atoms and R(2) is a hydrocarbon-comprising chain comprising from 3 to 30 carbon atoms, entrapped in the stearoyl inulin sugar gel matrix; a gel comprising hydrogenated polyisobutene; and a gel comprising fumed silica dimethyl silicate in C(15-19) Hydrocarbon. | 2009-03-05 |
| 20090060858 | HAIRCARE COMPOSITION - Hair care compositions contain from 0.1 to 12 weight percent of a silicone copolymer or saponification product thereof, prepared from silicones, at least 10% of which contain polymerizable groups, 0.5-14% of hydrophilic comonomers, and 30-99.9% of hydrophobic comonomers. The compositions exhibit good hair care properties. | 2009-03-05 |
| 20090060859 | IMIDAZOLIUM ALKYL (METH)ACRYLATE POLYMERS - The present invention relates to the use of imidazolium alkyl(meth)acrylate homo- and copolymers in cosmetic preparations and to the corresponding cosmetic preparations. | 2009-03-05 |
| 20090060860 | BETA-CYCLODEXTRINS AS NUCLEATING AGENTS FOR POLY(LACTIC ACID) - The use of β-CDs as nucleating agents for PLA to provide an increase in polymer crystallinity is described. The improvement in increased crystallinity is related to the percentage of β-CDs used. For the analyzed films, crystallinity was approximately 1.47% in the absence of a nucleating agent, and approximately 17.85% in the presence of the maximum amount of nucleating agent tested (e.g., 30%). Thus, improvement in processability, producability, and heat resistance of PLA will depend on the amount of β-CDs loaded. Additionally, loading PLA with β-CDs carrying an antifungal volatile is an effective way to increase PLA crystallinity besides avoiding fungal development when used in active packaging. In this case, the antifungal volatiles, along with changes in headspace concentration because of changes in crystallinity, may prolong the fresh produce shelf life. | 2009-03-05 |
| 20090060861 | Stabilized Polypeptide Formulations - The present invention relates to a pharmaceutical formulation comprising a polypeptide and a buffer selected from the group consisting of diethylmalonic acid, trimellitic acid, shikimic acid, glycinamid, 2-amino-2-methyl-1,3-propanediol (AMPD) and tetraethylammonium (T.E.A.) or salts thereof. Further more the invention relates to a method for improving stability of a polypeptide in a purification process comprising the step of applying a buffer selected from the group consisting of diethylmalonic acid, trimellitic acid, shikimic acid, glycinamid, AMPD and T.E.A. or salts thereof to said purification process. | 2009-03-05 |
| 20090060862 | PEGylation by the Dock and Lock (DNL) Technique - The present invention concerns methods and compositions for forming PEGylated complexes of defined stoichiometry and structure. In preferred embodiments, the PEGylated complex is formed using dock-and-lock technology, by attaching a target agent to a DDD sequence and attaching a PEG moiety to an AD sequence and allowing the DDD sequence to bind to the AD sequence in a 2:1 stoichiometry, to form PEGylated complexes with two target agents and one PEG moiety. In alternative embodiments, the target agent may be attached to the AD sequence and the PEG to the DDD sequence to form PEGylated complexes with two PEG moieties and one target agent. In more preferred embodiments, the target agent may comprise any peptide or protein of physiologic or therapeutic activity. The PEGylated complexes exhibit a significantly slower rate of clearance when injected into a subject and are of use for treatment of a wide variety of diseases. | 2009-03-05 |
| 20090060863 | DERIVATIVES OF GROWTH HORMONE AND RELATED PROTEINS - The growth hormone supergene family comprises greater than 20 structurally related cytokines and growth factors. A general method is provided for creating site-specific, biologically active conjugates of these proteins. The method involves adding cysteine residues to non-essential regions of the proteins or substituting cysteine residues for non-essential amino acids in the proteins using site-directed mutagenesis and then covalently coupling a cysteine-reactive polymer or other type of cysteine-reactive moiety to the proteins via the added cysteine residue. Disclosed herein are preferred sites for adding cysteine residues or introducing cysteine substitutions into the proteins, and the proteins and protein derivatives produced thereby. | 2009-03-05 |
| 20090060864 | Methods for treatment of tumors and metastases using a combination of anti-angiogenic and immuno therapies - The invention provides methods for treating tumors and tumor metastases in a mammal comprising administering, to a mammal in need of treatment, a therapeutic amount of an antagonist sufficient to inhibit angiogenesis in combination with a therapeutic amount of anti-tumor immunotherapeutic agent, such as a anti-tumor antigen antibody/cytokine fusion protein having a cytokine and a recombinant immunoglobulin polypeptide chain sufficient to elicit a cytokine-specific biological response. | 2009-03-05 |
| 20090060865 | MAMMALIAN RECEPTOR PROTEINS; RELATED REAGENTS AND METHODS - Nucleic acids encoding mammalian, e.g., primate, receptors, purified receptor proteins and fragments thereof. Antibodies, both polyclonal and monoclonal, are also provided. Methods of using the compositions for both diagnostic and therapeutic utilities are described. | 2009-03-05 |
| 20090060866 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS I AND II - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formula I, II, III, I′, II′, I″, II″, Ia, IIa, or IIIa, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2009-03-05 |
| 20090060867 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS III AND VI - Provided herein are phosphadiazine polymerase inhibitor, for example, of Formula III, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2009-03-05 |
| 20090060868 | ALPHA-MSH THERAPIES FOR TREATMENT OF AUTOIMMUNE DISEASE - Methods and compositions for the enteral treatment of autoimmune disease such a multiple sclerosis with polypeptide therapeutics. Enteral therapeutics comprise monomeric alpha-MSH polypeptides such as ACTH. Therapeutic formulations of the invention may be used to reduce the incidence or severity of autoimmune disease. For instance methods for the oral treatment of multiple sclerosis with alpha-MSH and ACTH are described. | 2009-03-05 |
| 20090060869 | EJECTION LIQUID, EJECTION METHOD, METHOD OF MAKING DROPLETS FROM LIQUID, CARTRIDGE AND EJECTION DEVICE - The present invention provides a liquid composition, as an ejection liquid used for stably ejecting liquid droplets, including at least one kind of a protein and a peptide, and a compound having a betaine skeleton by application of thermal energy to the liquid; a method of making droplets form the liquid; and an ejection method and an ejection device suitable for utilizing protein liquid droplets. By adding a compound having a betaine skeleton to an aqueous solution of at least one kind of a protein and a peptide, the liquid composition is improved in stability for ejection by application of thermal energy. Further, a surfactant may be further added to the liquid composition containing the compound having a betaine skeleton, and in this case the effect of stable ejection can be obtained. | 2009-03-05 |
| 20090060870 | METHODS AND MEANS FOR THE TREATMENT OF HPV INDUCED INTRAEPITHELIAL NEOPLASIA - The current invention provides improved methods and means for the treatment of virally induced intraepithelial neoplasias of the ano-genital tract, such as HPV induced vulvar-, cervical-, vaginal-, penile- and anal intraepithelial neoplasias (VIN, CIN, VAIN, PIN and AIN). The invention provides a method of treatment of a subject suffering from an anogenital intraepithelial neoplasia comprising at least the steps of first determining whether the subject has a T-cell reactivity for viral early antigens, in particular high risk type HPV antigens; and subsequently a local treatment of the neoplasia with immune modulating compounds eliciting local inflammation if the subject scores positive for the T-cell reactivity, preferably a CD4+response against HPV early antigens. The invention also comprises methods and means to induce or further stimulate a cellular immune response against HPV antigens, prior to or during treatment with the immune modulating compound capable of eliciting a local inflammatory response. | 2009-03-05 |
| 20090060872 | PHOSPHADIAZINE HCV POLYMERASE INHIBITORS V - Provided herein are phosphadiazine polymerase inhibitor, for example, of any of Formulas V, V′, I″, II″, or Va, pharmaceutical compositions comprising the compounds, and processes of preparation thereof. Also provided are methods of their use for the treatment of an HCV infection in a host in need thereof. | 2009-03-05 |
| 20090060873 | Novel synthetic triterpenoids and methods of use in the treatment and prevention of multiple scleroris - The present invention overcomes limitations of the prior art by providing new compounds and methods for the treatment of conditions, such as neurodegenerative diseases (e.g., multiple sclerosis), psychiatric disorders (e.g., psychosis, bipolar disorder, depression, neuropathic pain), conditions involving CNS-mediated chronic pain, spinal cord injuries, and other diseases or injuries. | 2009-03-05 |
| 20090060874 | BICYCLIC PYRROLIDINE DERIVATIVES - The present invention discloses compounds of formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof: | 2009-03-05 |
| 20090060875 | HCV Vaccines for Chronic HCV Patients - The invention discloses the use of polycationic compounds for the preparation and manufacturing of medicaments, pharmaceutical compositions, especially vaccines for the treatment of patients with HCV chronic infections. | 2009-03-05 |
| 20090060876 | Orally Used Compatible Solutes Containing Agents - The invention relates to the use of compatible solutes, especially ectoine, hydroxyectoine, di-myo-inositol phosphate (DIP), cyclic 2,3 diphosphoglycerate (cDPG), 1,1-di-glycerol phosphate (DGP), β-mannosylglycerate (firoin), β-mannosylglyceramide (firoin A), proline betaine and/or derivatives as well as combinations thereof for the production of an agent aimed at preventing and treating gastrointestinal and amyloidal diseases, with agents containing said active ingredients being disclosed as well. | 2009-03-05 |
| 20090060877 | Use - Use of whole cells of bacteria from the genera of aerobic organisms in the order of Actinomycetales in the manufacture of a medicament for the treatment or prevention of Type II diabetes and/or obesity and methods of treating or preventing Type II diabetes and/or obesity in a subject by administering an effective amount of a composition comprising a whole cell of a bacterium from a genera of aerobic organisms in the order of Actinomycetales to said subject. Preferably the bacteria is from one or more of the following genera for example: | 2009-03-05 |
| 20090060878 | Oral Compositions, Products And Methods Of Use - The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000 IU of cholecalciferol, per dose of the composition. | 2009-03-05 |
| 20090060879 | Oral Compositions, Products and Methods Of Use - The present invention comprises an oral composition. More particularly to a method of treating and preventing a respiratory tract infection and providing energy, relieving stress, and mood enhancing benefits to a human comprising: the steps of administering to a human a composition comprising from about 450 IU to about 500,000 IU of cholecalciferol, per dose of the composition. | 2009-03-05 |
| 20090060880 | Biocontrol of Varroa Mites - A biopesticide formulation using isolates of the fungus | 2009-03-05 |
| 20090060881 | Gamma secretase inhibitor for treatment of herpesvirus infection - This invention relates to methods and compositions for the treatment of malignancies associated with gamma-herpesvirus infection. Specifically, the invention relates to the use of gamma-secretase inhibitors to prevent the production of intracellular Notch1 thereby arresting the growth of the infected cells. | 2009-03-05 |
| 20090060882 | Method Of Treating Mouse Carrying Human Hepatocytes - Human adult hepatocytes are transplanted into an immunodeficient hepatopathy mouse and then human growth hormone is administered to the mouse to thereby elevate twice or more the replacement ratio by the human adult hepatocytes having been transplanted. Further, human growth hormone is administered to an immunodeficient hepatopathy mouse carrying human young hepatocytes transplanted thereinto so as to improve fatty liver of the mouse in which about 70% or more of the hepatocytes have been replaced by the human hepatocytes. | 2009-03-05 |
| 20090060883 | COMPOSITION FOR PROMOTION OF BONE GROWTH AND MAINTENANCE OF BONE HEALTH - The present invention relates to a composition for maintenance of bone health or prevention, alleviation and/or treatment of bone disorders. It also relates to the use of the composition in the manufacture of a nutritional product, a supplement, a treat or a medicament; and a method of promoting bone growth or for the maintenance of bone health, which comprises administering an effective amount of the composition. | 2009-03-05 |
| 20090060884 | CONCENTRATION OF STEM CELLS OBTAINED DURING ORTHOPAEDIC SURGERIES - Methods for isolating and concentrating bone marrow stromal cells drawn from various surgical sites (for example, the proximal humeral head during rotator cuff repair, or the distal femur during ACL surgery) during arthroscopic or open orthopaedic surgery. The pluripotent cells obtained from the bone marrow aspirate can then be reimplanted during the same surgery to improve healing. | 2009-03-05 |
| 20090060885 | Composition For Treatment of Articular Cartilage Damage - Disclosed is a composition for the treatment of cartilage or bone damage or loss or defect. The composition comprises mesenchymal stem cells separated from umbilical cord blood and/or mesenchymal stem cells proliferated and/or differentiated. The composition also comprise chondrocytes and/or chondroblasts, or osteocytes and/or osteoblasts, differentiated from the mesenchymal stem cells separated from the umbilical cord blood. | 2009-03-05 |
| 20090060886 | TRANSLUMINAL APPLICATION OF ADULT STEM CELLS FOR BODY ORGAN TISSUE REPAIR - A method for repairing tissue of a selected organ from among heart, brain, liver, pancreas, kidney, glands, and muscles in a patient's body. Adult stem cells that have the capability to repair tissue of the selected organ are recovered by harvesting from the patient's body. The harvested stem cells are then intraluminally applied through a designated natural body vessel. During the time the stem cells are being applied to the targeted tissue downstream, the designated vessel or duct is selectively occluded to increase concentration and pressure of the applied adult stem cells by the vessel. | 2009-03-05 |
| 20090060887 | Method for treating the pancreas of a human patient - The invention involves a method for treating a pancreas of a human patient by rejuvenating and restoring function of such pancreas by the steps of locally inserting a growth factor, such as stem cells and germinal cells, into the body of the patient into or around the pancreas and thereby growing Islets of Langerhans in the pancreas and restoring insulin production. | 2009-03-05 |
| 20090060888 | Regulated transcription of targeted genes and other biological events - Dimerization and oligomerization of proteins are general biological control mechanisms that contribute to the activation of cell membrane receptors, transcription factors, vesicle fusion proteins, and other classes of intra- and extracellular proteins. We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins. In principle, any two target proteins can be induced to associate by treating the cells or organisms that harbor them with cell permeable, synthetic ligands. To illustrate the practice of this invention, we have induced: (1) the intracellular aggregation of the cytoplasmic tail of the ζ chain of the T cell receptor (TCR)-CD3 complex thereby leading to signaling and transcription of a reporter gene, (2) the homodimerization of the cytoplasmic tail of the Fas receptor thereby leading to cell-specific apoptosis (programmed cell death) and (3) the heterodimerization of a DNA-binding domain (Gal4) and a transcription-activation domain (VP16) thereby leading to direct transcription of a reporter gene. | 2009-03-05 |
| 20090060889 | Ii-RNAi involved Ii suppression in cancer immunotherapy - Provided are compositions and methods involving the inhibition of Ii expression in cells for the purpose of altering antigen presentation pathways. Human Ii-RNAi constructs that effectively inhibit Ii expression in human cancer cells have been generated. The combination of different Ii-RNAi constructs that target different positions of Ii mRNA has a synergistic effect on Ii inhibition. Furthermore, specific promoters for driving Ii-RNAi expression are critical for the activity of Ii-RNAi in different types of cells. Active Ii-RNAi sequences were cloned into plasmids in which Ii-RNAi sequences are driven by either a CMV or an EF-1α promoter. Compositions and methods are disclosed for inhibiting Ii and treating cancer. Provided are siRNAs and expression constructs comprising DNA sequences which encode siRNAs effective to inhibit Ii expression, cells containing such DNA constructs or siRNAs, and methods for use of the same. | 2009-03-05 |
| 20090060890 | SELECTIVE CYTOPHERESIS DEVICES AND RELATED METHODS THEREOF - The present invention relates to systems and devices to treat and/or prevent inflammatory conditions within a subject and to related methods. More particularly, the invention relates to systems, devices, and related methods that sequester leukocytes and/or platelets and then inhibit their inflammatory action. | 2009-03-05 |
| 20090060891 | High Concentration Self-Microemulsifying Coenzyme Q10 Preparations For Nutritional Use - A method and composition are presented for enhancing the dissolution and bioavailable properties of CoQ10 nutritional supplements and/or therapeutic agents for a human being and other mammals. The method includes preparing an anhydrous self-microemulsifying base composition by combining: CoQ10, a water-immiscible, and a non-ionic surfactant, containing polyethylene glycol. For an orally administered CoQ10 nutritional supplement in a capsule formulation, a unit dosage from the composition is added to a dissolvable capsule, preferably a soft gelatin capsule, in order to form the nutritional supplement. When a capsule containing the self-microemulsifying composition enters the digestive tract, the temperature of the body's digestive juices warms the composition, causing any of the CoQ10 that may have re-crystallized out of the composition to become re-dissolved into the composition before the capsule dissolves. The re-dissolution of CoQ10 is bioavailable when the capsule dissolves. Upon dissolution of the capsule, the self-microemulsifying composition comes into contact with the digestive juices and naturally forms micellar-type bioavaible microemulsions, consisting of micelles containing CoQ10. In addition to the capsule formulation, the invention includes parenteral, liquid, topical and ophthalmic formulations. | 2009-03-05 |
